PRMT3

Summary

PRMT3 (protein arginine methyltransferase 3, HGNC:30163) is a protein-coding gene on chromosome 11p15.1, encoding Protein arginine N-methyltransferase 3 (O60678). Protein-arginine N-methyltransferase that catalyzes both the monomethylation and asymmetric dimethylation of the guanidino nitrogens of arginine residues in target proteins, and therefore falls into the group of type I methyltransferases.

This gene belongs to the protein arginine methyltransferase (PRMT) family. The encoded enzyme catalyzes the methylation of guanidino nitrogens of arginyl residues of proteins. The enzyme acts on 40S ribosomal protein S2 (rpS2), which is its major in-vivo substrate, and is involved in the proper maturation of the 80S ribosome. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10196 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 85 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005788

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30163
Approved symbol	PRMT3
Name	protein arginine methyltransferase 3
Location	11p15.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000185238
Ensembl biotype	protein_coding
OMIM	603190
Entrez	10196

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 3 nonsense_mediated_decay, 1 retained_intron

ENST00000330796, ENST00000331079, ENST00000437750, ENST00000525188, ENST00000526583, ENST00000529592, ENST00000862431, ENST00000862432, ENST00000862433, ENST00000862434, ENST00000962519, ENST00000962520, ENST00000962521

RefSeq mRNA: 3 — MANE Select: NM_005788 NM_001145166, NM_001145167, NM_005788

CCDS: CCDS44554, CCDS7853

Canonical transcript exons

ENST00000331079 — 16 exons

Exon	Start	End
ENSE00001293242	20388019	20388154
ENSE00002154431	20387716	20387774
ENSE00002195347	20508304	20509338
ENSE00003469168	20493919	20493969
ENSE00003507093	20397577	20397721
ENSE00003515447	20407911	20408032
ENSE00003531785	20389744	20389826
ENSE00003534033	20395803	20395962
ENSE00003550456	20402919	20402984
ENSE00003553403	20494167	20494254
ENSE00003592179	20464460	20464546
ENSE00003592826	20392897	20392999
ENSE00003630415	20426766	20426865
ENSE00003639695	20392211	20392260
ENSE00003644096	20461980	20462167
ENSE00003673129	20452130	20452208

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 84.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.2870 / max 238.3430, expressed in 1808 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
113426	8.3473	1633
113424	8.0203	1735
113425	2.6012	1337
113427	0.2408	105
206225	0.0775	25

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	84.63	gold quality
calcaneal tendon	UBERON:0003701	84.55	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.39	gold quality
gingival epithelium	UBERON:0001949	84.29	gold quality
gastrocnemius	UBERON:0001388	83.86	gold quality
left lobe of thyroid gland	UBERON:0001120	83.37	gold quality
muscle of leg	UBERON:0001383	83.17	gold quality
thyroid gland	UBERON:0002046	82.96	gold quality
germinal epithelium of ovary	UBERON:0001304	82.91	gold quality
right lobe of thyroid gland	UBERON:0001119	82.76	gold quality
adrenal tissue	UBERON:0018303	82.74	gold quality
islet of Langerhans	UBERON:0000006	82.16	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	81.69	gold quality
right adrenal gland cortex	UBERON:0035827	81.21	gold quality
left adrenal gland	UBERON:0001234	81.19	gold quality
right adrenal gland	UBERON:0001233	81.13	gold quality
left adrenal gland cortex	UBERON:0035825	81.08	gold quality
gingiva	UBERON:0001828	81.01	gold quality
palpebral conjunctiva	UBERON:0001812	80.91	gold quality
hindlimb stylopod muscle	UBERON:0004252	80.79	gold quality
stromal cell of endometrium	CL:0002255	80.53	gold quality
ganglionic eminence	UBERON:0004023	80.50	gold quality
rectum	UBERON:0001052	80.21	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.19	gold quality
heart left ventricle	UBERON:0002084	80.19	gold quality
adrenal gland	UBERON:0002369	80.17	gold quality
esophagus mucosa	UBERON:0002469	80.14	gold quality
monocyte	CL:0000576	80.08	gold quality
right atrium auricular region	UBERON:0006631	80.05	gold quality
mononuclear cell	CL:0000842	79.96	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.06
E-MTAB-6058	no	165.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

70 targeting PRMT3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-548D-3P	99.87	70.67	4362

Literature-anchored findings (GeneRIF, showing 21)

• PRMT3 is a ribosomal protein methyltransferase that affects the cellular level of ribosomal subunits. (PMID:15175657)
• DAL-1/4.1B protein significantly inhibits PRMT3 methylation of cellular substrates, which may affect mechanism through which DAL-1/4.1B affects tumor cell growth. (PMID:15334060)
• Type I Arginine Methyltransferases PRMT1 and PRMT-3 Act Distributively (PMID:19158082)
• results suggest that the pathological mutation in the PABPN1 gene alters the protein conformation and induces a preferential interaction with type I PRMTs and Hsp70 chaperones (PMID:19641605)
• The Tyr87Cys and Tyr87Glu-PRMT3 variants had markedly decreased affinity to ribosomal protein S2 and, consequently, reduced enzymatic activity compared to the wild-type enzyme. (PMID:21059412)
• release of VHL30 from the E3 ligase complex, promotes the binding of VHL30 to a protein arginine methyltransferase, PRMT3 (PMID:21942715)
• The crystal structure of PRMT3 in complex with an inhibitor as well as kinetic analysis reveals an allosteric site of inhibition. (PMID:22795084)
• Mutational defects in PRMT3 is not the cause of frontotemporal lobar degeneration. (PMID:23635657)
• results show that protein arginine methyl transferase (PRMT)-3 and -5 methylate NaV1.5 in vitro, interact with NaV1.5 in human embryonic kidney (HEK) cells, and increase NaV1.5 current density (PMID:23912080)
• This work profilies substrates of protein arginine N-methyltransferase 3 with S-adenosyl-L-methionine analogues. (PMID:24320160)
• PRMT3 translocation by palmitic acid is coupled to the binding of LXRalpha, which is responsible for the onset of fatty liver. (PMID:25187371)
• Findings uncover the existence of an extra-ribosomal complex consisting of PDCD2L, RPS2, and PRMT3 and support a role for PDCD2L in the late maturation of 40S ribosomal subunits. (PMID:27697862)
• ZNF277 and PRMT3 compete for uS5 binding, because overexpression of PRMT3 inhibited the formation of the ZNF277-uS5 complex, whereas depletion of cellular ZNF277 resulted in increased levels of uS5-PRMT3. (PMID:30530495)
• PRMT3 is an essential regulator of mesenchymal stem cell-mediated osteogenesis and bone homeostasis. (PMID:31378783)
• PRMT3 interacts with ALDH1A1 and regulates gene-expression by inhibiting retinoic acid signaling. (PMID:33495566)
• Arginine methyltransferase PRMT3 promote tumorigenesis through regulating c-MYC stabilization in colorectal cancer. (PMID:33991650)
• Decreased nitric oxide content mediated by asymmetrical dimethylarginine and protein l-arginine methyltransferase 3 in macrophages induces trophoblast apoptosis: a potential cause of recurrent miscarriage. (PMID:34647126)
• Protein arginine methyltransferase 3: A crucial regulator in metabolic reprogramming and gene expression in cancers. (PMID:36400311)
• PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast. (PMID:36637351)
• PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. (PMID:37024475)
• PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma. (PMID:37973560)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	prmt3	ENSDARG00000019791
mus_musculus	Prmt3	ENSMUSG00000030505
rattus_norvegicus	Prmt3	ENSRNOG00000014829
drosophila_melanogaster	Art9	FBGN0038188
drosophila_melanogaster	Art6	FBGN0038189
drosophila_melanogaster	Art3	FBGN0038306
drosophila_melanogaster	CG32152	FBGN0052152

Paralogs (7): PRMT8 (ENSG00000111218), PRMT1 (ENSG00000126457), PRMT7 (ENSG00000132600), CARM1 (ENSG00000142453), PRMT2 (ENSG00000160310), PRMT9 (ENSG00000164169), PRMT6 (ENSG00000198890)

Protein

Protein identifiers

Protein arginine N-methyltransferase 3 — O60678 (reviewed: O60678)

Alternative names: Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3

All UniProt accessions (3): E9PLF6, E9PRB4, O60678

UniProt curated annotations — full annotation on UniProt →

Function. Protein-arginine N-methyltransferase that catalyzes both the monomethylation and asymmetric dimethylation of the guanidino nitrogens of arginine residues in target proteins, and therefore falls into the group of type I methyltransferases. Catalyzes the asymmetric arginine dimethylation at multiple sites in the Arg/Gly-rich region of small ribosomal subunit protein uS5/RPS2. Also appears to methylate other ribosomal proteins. May regulate retinoic acid synthesis and signaling by inhibiting ALDH1A1 retinal dehydrogenase activity. Contributes to methylation of histone H4 ‘Arg-3’, a specific tag for epigenetic transcriptional activation. Mediates asymmetric arginine dimethylation of histone H4 ‘Arg-3’ (H4R3me2a) in the promoter region of miRNA miR-3648, to promote its transcription and osteogenesis.

Subunit / interactions. Monomer and homodimer. Interacts with EPB41L3 (via FERM domain); the interaction is direct and inhibits the protein-arginine N-methyltransferase activity of PRMT3. Interacts with the 40S ribosomal protein RPS2/uS5. Interacts with ALDH1A1; the interaction is direct, inhibits ALDH1A1 aldehyde dehydrogenase activity and is independent of the methyltransferase activity of PRMT3. Interacts (via zinc-finger) with ZNF200 (via C-terminus); the interaction is direct and required to localize PRMT3 to the nucleus and inhibit its proteasomal degradation.

Subcellular location. Cytoplasm. Cytosol. Nucleus.

Activity regulation. Inhibited by N-ethylmaleimide and high concentrations of zinc chloride. Allosterically inhibited by SGC707. Allosterically inhibited by (1-(benzo[d][1,2,3]thiadiazol- 6-yl)-3-(2-cyclohexenylethyl)urea) and derivatives thereof.

Domain organisation. The C2H2-type zinc-finger is responsible for substrate specificity.

Similarity. Belongs to the class I-like SAM-binding methyltransferase superfamily. Protein arginine N-methyltransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
O60678-1	1	yes
O60678-2	2

RefSeq proteins (3): NP_001138638, NP_001138639, NP_005779* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR025799	Arg_MeTrfase	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR049009	ANM3_Znf-C2H2	Domain
IPR049482	ANM3-like_C2H2_Zf	Domain
IPR055135	PRMT_dom	Domain

Pfam: PF06325, PF21137, PF21336, PF22528

Enzyme classification (BRENDA):

• EC 2.1.1.319 — type I protein arginine methyltransferase (BRENDA: 13 organisms, 109 substrates, 121 inhibitors, 26 Km, 24 kcat entries)

Substrate kinetics (BRENDA)

16 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[HISTONE H2A]-L-ARGININE	0.0005–0.128	3
[HISTONE H3]-L-ARGININE	0.001–0.0282	3
[HISTONE H4]-L-ARGININE	0.0017–0.0388	3
[GRGGFGGRGGFRGGRGG]-L-ARGININE	0.0003–0.0008	2
[HISTONE H4(1-22) PEPTIDE]-L-ARGININE3	0.0002–0.0008	2
FYSGFNS-DIMETHYL-R8-P-DIMETHYL-R10-GRVYATSWY	0.0222	1
FYSGFNS-DIMETHYL-R8-PRG-DIMETHYL-R12-VYATSWY	0.0007	1
FYSGFNS-DIMETHYL-R8-PRGRVYATSWY	0.0006	1
FYSGFNSRP-DIMETHYL-R10-G-DIMETHYL-R12-VYATSWY	0.008	1
FYSGFNSRP-METHYL-R10-GRVYATSWY	0.0007	1
[HISTONE H4(1-16) PEPTIDE]-L-ARGININE3	0.0003	1
[PABPN1 MUTANT DELTAC20]-L-ARGININE	0.0004	1
[PABPN1 MUTANT DELTAC27]-L-ARGININE	0.0001	1
[PABPN1 MUTANT DELTAC33]-L-ARGININE	—	1
[PABPN1 MUTANT DELTAC40]-L-ARGININE	0.0032	1

Catalyzed reactions (Rhea), 2 shown:

• L-arginyl-[protein] + 2 S-adenosyl-L-methionine = N(omega),N(omega)-dimethyl-L-arginyl-[protein] + 2 S-adenosyl-L-homocysteine + 2 H(+) (RHEA:48096)
• L-arginyl-[protein] + S-adenosyl-L-methionine = N(omega)-methyl-L-arginyl-[protein] + S-adenosyl-L-homocysteine + H(+) (RHEA:48100)

UniProt features (71 total): strand 16, helix 13, mutagenesis site 9, binding site 6, turn 5, modified residue 4, sequence variant 3, sequence conflict 3, region of interest 3, active site 2, initiator methionine 1, chain 1, site 1, domain 1, splice variant 1, zinc finger region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
8SHR	X-RAY DIFFRACTION	1.92
2FYT	X-RAY DIFFRACTION	2
3SMQ	X-RAY DIFFRACTION	2
8G2G	X-RAY DIFFRACTION	2.02
8G2F	X-RAY DIFFRACTION	2.06
4QQN	X-RAY DIFFRACTION	2.08
8SHB	X-RAY DIFFRACTION	2.09
4RYL	X-RAY DIFFRACTION	2.1
8SIO	X-RAY DIFFRACTION	2.2
4HSG	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60678-F1	85.63	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 87 (not phosphorylated); 329; 338

Ligand- & substrate-binding residues (6): 239; 263; 285; 313; 314; 343

Post-translational modifications (4): 2, 25, 27, 171

Mutagenesis-validated functional residues (9):

Position	Phenotype
87	markedly reduced affinity for rps2.
87	no effect on interaction with rps2.
338	loss of catalytic activity. no effect on aldh1a1 activity regulation.
403	reduces catalytic activity.
464	loss of interaction with aldh1a1.
465	loss of interaction with aldh1a1.
466	loss of interaction with aldh1a1.
468	loss of interaction with aldh1a1.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-3214858	RMTs methylate histone arginines
R-HSA-8876725	Protein methylation
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-392499	Metabolism of proteins
R-HSA-4839726	Chromatin organization
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 317 (showing top): RNGTGGGC_UNKNOWN, E2F_Q4_01, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GCANCTGNY_MYOD_Q6, AREB6_03, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_NEGATIVE_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_OSTEOBLAST_DIFFERENTIATION, MEF2_02, TAL1ALPHAE47_01, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_VITAMIN_METABOLIC_PROCESS, SRF_Q5_01

GO Biological Process (8): chromatin remodeling (GO:0006338), regulation of DNA-templated transcription (GO:0006355), negative regulation of protein ubiquitination (GO:0031397), methylation (GO:0032259), positive regulation of osteoblast differentiation (GO:0045669), transcription initiation-coupled chromatin remodeling (GO:0045815), negative regulation of retinoic acid biosynthetic process (GO:1900053), peptidyl-arginine methylation (GO:0018216)

GO Molecular Function (10): methyltransferase activity (GO:0008168), zinc ion binding (GO:0008270), protein-arginine N-methyltransferase activity (GO:0016274), protein-arginine omega-N monomethyltransferase activity (GO:0035241), protein-arginine omega-N asymmetric methyltransferase activity (GO:0035242), histone methyltransferase activity (GO:0042054), histone H4R3 methyltransferase activity (GO:0044020), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Post-translational protein modification	1
Chromatin organization	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-arginine N-methyltransferase activity	3
cellular anatomical structure	3
protein methyltransferase activity	2
chromatin organization	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
protein ubiquitination	1
regulation of protein ubiquitination	1
negative regulation of protein modification by small protein conjugation or removal	1
metabolic process	1
osteoblast differentiation	1
positive regulation of cell differentiation	1
regulation of osteoblast differentiation	1
transcription initiation at RNA polymerase II promoter	1
positive regulation of gene expression, epigenetic	1
retinoic acid biosynthetic process	1
negative regulation of hormone metabolic process	1
negative regulation of isoprenoid metabolic process	1
negative regulation of vitamin metabolic process	1
negative regulation of lipid biosynthetic process	1
regulation of retinoic acid biosynthetic process	1
protein methylation	1
peptidyl-arginine modification	1
transferase activity, transferring one-carbon groups	1
transition metal ion binding	1
arginine N-methyltransferase activity	1
histone modifying activity	1
histone H4 methyltransferase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

2474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRMT3	EPB41L3	Q9Y2J2	914
PRMT3	PRMT5	O14744	892
PRMT3	RPS2	P15880	843
PRMT3	PRMT1	Q99873	838
PRMT3	CARM1	Q86X55	790
PRMT3	SETD7	Q8WTS6	708
PRMT3	SUV39H2	Q9H5I1	637
PRMT3	HNRNPA1	P09651	624
PRMT3	EZH2	Q15910	615
PRMT3	HNRNPDL	O14979	608
PRMT3	PDCD2L	Q9BRP1	591
PRMT3	KMT5A	Q9NQR1	585
PRMT3	SMYD3	Q9H7B4	581
PRMT3	WDR77	Q9BQA1	576
PRMT3	KDM1A	O60341	562

IntAct

75 interactions, top by confidence:

A	B	Type	Score
PRMT3	RPS2	psi-mi:“MI:0915”(physical association)	0.810
RPS2	PRMT3	psi-mi:“MI:0915”(physical association)	0.810
PRMT3	RPS2	psi-mi:“MI:0914”(association)	0.810
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
PRMT3	PIH1D2	psi-mi:“MI:0915”(physical association)	0.560
PRMT3	BEND7	psi-mi:“MI:0915”(physical association)	0.560
PRMT3	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
FKBP6	EEF2K	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
TSKS	RGPD8	psi-mi:“MI:0914”(association)	0.530
PDCD2L	PRMT3	psi-mi:“MI:0914”(association)	0.530
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
SCN5A	PRMT3	psi-mi:“MI:2364”(proximity)	0.470
SCN5A	PRMT3	psi-mi:“MI:0915”(physical association)	0.470
SH2D1B	PRMT3	psi-mi:“MI:0915”(physical association)	0.400
HNRNPK	PRMT3	psi-mi:“MI:0915”(physical association)	0.400
PPARD	PRMT3	psi-mi:“MI:0915”(physical association)	0.370
PRMT3	RASSF2	psi-mi:“MI:0915”(physical association)	0.370
Ranbp2	POM121C	psi-mi:“MI:0914”(association)	0.350
HNRNPD	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
ORF2	PRMT3	psi-mi:“MI:0914”(association)	0.350
PARP8	PRMT3	psi-mi:“MI:0914”(association)	0.350
PRMT3	CSTA	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (248): RPS2 (Biochemical Activity), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Proximity Label-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS), PRMT3 (Two-hybrid), PRMT3 (Affinity Capture-MS), PRMT3 (Affinity Capture-MS)

ESM2 similar proteins: A0JMU5, A1A4L5, A2AV36, A2Y8B9, B0X4N1, B3DLB3, B3M1E1, B3MF31, B3P4N5, B4GZ20, B4HJC0, B4I8G2, B4JXV2, B4KA23, B4LVS8, B4NKI9, B4P925, B4PVH6, B4QI55, B4QVW6, B6DMK2, D9IVE5, O14727, O60678, O70467, O88879, Q0V9P1, Q16NS8, Q29B63, Q3EBC8, Q3U213, Q3U3W5, Q4SBY6, Q5RAY7, Q5ZIB9, Q6P2P2, Q6P5U7, Q6PCI6, Q7QIL2, Q80VJ4

Diamond homologs: A0A3Q0KHE7, A0A411EW25, A0JMU5, A2AV36, A2Y953, A2YPT7, A2Z0C0, A3KPF2, A6QQV6, A8IEF3, B0JYW5, B0W3L6, B3DLB3, B3M1E1, B3P4N5, B4GZ20, B4HJC0, B4JXV2, B4KA23, B4LVS8, B4MNL1, B4NKI9, B4PVH6, B4QVW6, D9IVE5, O13648, O60678, O70467, O82210, P38074, P55345, Q08A71, Q0J2C6, Q174R2, Q28F07, Q29B63, Q3U3W5, Q4AE70, Q54EF2, Q54HI0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PRMT3	“down-regulates activity”	ALDH1A1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3604 predictions. Top by Δscore:

Variant	Effect	Δscore
11:20388153:AG:A	donor_loss	1.0000
11:20388154:GG:G	donor_loss	1.0000
11:20388156:T:A	donor_loss	1.0000
11:20395798:TTTA:T	acceptor_loss	1.0000
11:20395799:TTA:T	acceptor_loss	1.0000
11:20395800:TA:T	acceptor_loss	1.0000
11:20395801:A:AG	acceptor_gain	1.0000
11:20395802:G:A	acceptor_loss	1.0000
11:20395802:G:GA	acceptor_gain	1.0000
11:20395802:GAT:G	acceptor_gain	1.0000
11:20395937:GCAC:G	donor_gain	1.0000
11:20395960:G:GT	donor_gain	1.0000
11:20395960:GAA:G	donor_gain	1.0000
11:20395963:G:GG	donor_gain	1.0000
11:20402914:CCTAG:C	acceptor_loss	1.0000
11:20402915:CTAGG:C	acceptor_loss	1.0000
11:20402916:TAG:T	acceptor_loss	1.0000
11:20402918:G:A	acceptor_loss	1.0000
11:20402982:AAGG:A	donor_loss	1.0000
11:20402984:GGT:G	donor_loss	1.0000
11:20402985:G:GC	donor_loss	1.0000
11:20402986:T:A	donor_loss	1.0000
11:20407900:A:AG	acceptor_gain	1.0000
11:20407901:A:G	acceptor_gain	1.0000
11:20407904:A:AG	acceptor_gain	1.0000
11:20407910:GGTA:G	acceptor_gain	1.0000
11:20408028:ATAAG:A	donor_loss	1.0000
11:20408029:TAAG:T	donor_loss	1.0000
11:20408030:AAG:A	donor_loss	1.0000
11:20408033:GT:G	donor_loss	1.0000

AlphaMissense

3522 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:20402944:G:C	R244P	1.000
11:20397714:T:C	M233T	0.999
11:20402919:G:C	D236H	0.999
11:20407915:T:A	V259D	0.999
11:20426858:A:T	E329V	0.999
11:20426860:T:A	W330R	0.999
11:20426860:T:C	W330R	0.999
11:20452130:G:C	G332R	0.999
11:20452145:T:C	F337L	0.999
11:20452147:T:A	F337L	0.999
11:20452147:T:G	F337L	0.999
11:20452149:A:T	E338V	0.999
11:20493934:T:C	F455L	0.999
11:20493936:T:A	F455L	0.999
11:20493936:T:G	F455L	0.999
11:20494206:T:A	W480R	0.999
11:20494206:T:C	W480R	0.999
11:20494208:G:C	W480C	0.999
11:20494208:G:T	W480C	0.999
11:20392942:T:A	W115R	0.998
11:20392942:T:C	W115R	0.998
11:20397714:T:G	M233R	0.998
11:20397715:G:A	M233I	0.998
11:20397715:G:C	M233I	0.998
11:20397715:G:T	M233I	0.998
11:20402920:A:C	D236A	0.998
11:20402920:A:T	D236V	0.998
11:20407939:G:A	G267E	0.998
11:20407957:C:A	A273D	0.998
11:20407990:T:A	V284D	0.998

dbSNP variants (sampled 300 via entrez): RS1000120912 (11:20440533 T>G), RS1000124689 (11:20456608 T>C), RS1000200330 (11:20397043 C>G), RS1000230690 (11:20493896 A>C,G), RS1000232884 (11:20407489 T>G), RS1000265163 (11:20479328 T>A), RS1000283276 (11:20493583 A>G,T), RS1000283931 (11:20450279 T>G), RS1000347358 (11:20395443 A>C), RS1000378301 (11:20480876 G>C), RS1000413527 (11:20414018 A>G), RS1000426964 (11:20443761 G>A), RS1000430153 (11:20499827 C>T), RS1000435857 (11:20443467 C>A,G), RS1000463858 (11:20487392 C>T)

Disease associations

OMIM: gene MIM:603190 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002754_2	Response to inhaled glucocorticoid treatment in asthma (change in FEV1)	6.000000e-11
GCST005024_106	Pursuit maintenance gain	8.000000e-06
GCST008447_2	Number of alcoholic drinks required to feel an effect (long-term average)	6.000000e-10
GCST009738_2	Carotid intima media thickness (maximum)	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005921	FEV change measurement
EFO:0008433	pursuit maintenance gain measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5891 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,522 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1088977	ADEMETIONINE	3	1,522

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 2.1.1.- Protein arginine N-methyltransferases

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
SGC707	Negative	7.28	pKd
MS023	Inhibition	7.26	pKi
compound 1 [PMID: 22795084]	Inhibition	5.6	pIC50

Binding affinities (BindingDB)

2 measured of 5 human assays (5 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
MS023 (Compound 3)	KI	23 nM
N1-Methyl-N1-((4-(3-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)ethane-1,2-diamine (Compound 2)	KI	120 nM

ChEMBL bioactivities

125 potent at pChembl≥5 of 146 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	IC50	1.7	nM	CHEMBL5559689
8.40	IC50	4	nM	CHEMBL3901808
8.00	IC50	10	nM	CHEMBL4079503
7.77	IC50	17	nM	CHEMBL4076640
7.72	IC50	19	nM	CHEMBL4061429
7.72	IC50	19	nM	CHEMBL4077534
7.72	IC50	19	nM	CHEMBL4072005
7.66	IC50	22	nM	CHEMBL4094513
7.66	IC50	22	nM	CHEMBL4061085
7.66	IC50	22	nM	CHEMBL4071410
7.62	IC50	24	nM	CHEMBL4062783
7.51	IC50	31	nM	CHEMBL4072005
7.46	IC50	35	nM	CHEMBL4086964
7.44	IC50	36	nM	CHEMBL4095787
7.34	IC50	46	nM	CHEMBL4082966
7.28	Kd	53	nM	CHEMBL4072005
7.26	IC50	55	nM	CHEMBL4105488
7.26	Ki	55	nM	CHEMBL3901808
7.21	IC50	61	nM	CHEMBL4097428
7.18	IC50	66	nM	CHEMBL4072005
7.08	IC50	84	nM	CHEMBL4087094
7.07	Kd	85	nM	CHEMBL4072005
7.06	IC50	87	nM	CHEMBL4082359
7.04	IC50	91	nM	CHEMBL4072005
6.96	IC50	110	nM	S-ADENOSYLHOMOCYSTEINE
6.94	IC50	114	nM	CHEMBL4065941
6.92	IC50	119	nM	CHEMBL3901808
6.92	IC50	119	nM	CHEMBL5633822
6.87	IC50	134	nM	CHEMBL4077534
6.87	IC50	134	nM	CHEMBL4071410
6.87	IC50	134	nM	CHEMBL2325198
6.82	IC50	150	nM	CHEMBL4090733
6.80	IC50	158	nM	CHEMBL4074611
6.78	IC50	166	nM	CHEMBL4097411
6.71	IC50	194	nM	CHEMBL4059940
6.65	IC50	225	nM	CHEMBL4072005
6.64	IC50	230	nM	CHEMBL2325198
6.62	IC50	240	nM	CHEMBL4062783
6.54	IC50	292	nM	CHEMBL4063230
6.54	IC50	291	nM	CHEMBL4101037
6.53	IC50	295	nM	CHEMBL4081032
6.52	IC50	300	nM	CHEMBL2325177
6.49	IC50	321	nM	CHEMBL5613745
6.49	IC50	321	nM	CHEMBL5613785
6.49	IC50	321	nM	CHEMBL5612658
6.44	IC50	360	nM	CHEMBL2325197
6.38	IC50	421	nM	CHEMBL4104833
6.32	IC50	480	nM	CHEMBL2325183
6.32	IC50	477	nM	CHEMBL4084879
6.32	IC50	476	nM	CHEMBL4100373

PubChem BioAssay actives

121 with measured affinity, of 370 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N’-[[5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N’-dimethylethane-1,2-diamine	2069866: Inhibition of N-terminal GST-tagged human PRMT3 (2 to end residues) expressed in Escherichia coli using SAM and Histone (1 to 21 residues) as substrate preincubated for 60 mins followed by substrate addition and measured after 40 mins by Topcount reader based analysis	ic50	0.0017	uM
N’-methyl-N’-[[4-(4-propan-2-yloxyphenyl)-1H-pyrrol-3-yl]methyl]ethane-1,2-diamine	1319863: Inhibition of human PRMT3 assessed as inhibition of methylation activity using biotin-labeled peptide as substrate and [3H]-SAM by scintillation proximity assay	ic50	0.0040	uM
1-(3-fluoroisoquinolin-6-yl)-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0100	uM
1-[2-(azepan-1-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0170	uM
1-(8-chloroisoquinolin-6-yl)-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0190	uM
1-(7-fluoroisoquinolin-6-yl)-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0190	uM
1-isoquinolin-6-yl-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0190	uM
1-[2-(8-azabicyclo[3.2.1]octan-8-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0220	uM
1-[2-(2,5-dimethylpyrrolidin-1-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0220	uM
N’-[[2-(2-chlorophenyl)sulfanylphenyl]methyl]-N’-methylethane-1,2-diamine	1471457: Inhibition of PRMT3 (unknown origin) incubated for 15 mins followed by substrate addition measured after 60 mins by AlphaLisa method	ic50	0.0220	uM
1-isoquinolin-6-yl-3-[2-oxo-2-(3,3,4,4-tetrafluoropyrrolidin-1-yl)ethyl]urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0240	uM
1-[2-(4,4-difluoropiperidin-1-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0350	uM
1-(7-methylisoquinolin-6-yl)-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0360	uM
1-[2-(7-azabicyclo[2.2.1]heptan-7-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0460	uM
1-[2-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0550	uM
1-[2-(azetidin-1-yl)-2-oxoethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0610	uM
1-isoquinolin-6-yl-3-(2-oxo-2-piperidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0840	uM
N-cyclopentyl-2-(isoquinolin-6-ylcarbamoylamino)-N-methylacetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.0870	uM
(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	1689512: Inhibition of recombinant human PRMT8 using histone H4 as substrate by hotspot assay	ic50	0.1100	uM
N,N-diethyl-2-(isoquinolin-6-ylcarbamoylamino)acetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1140	uM
N’-[[4-(4-propan-2-yloxyphenyl)-1H-pyrrol-3-yl]methyl]ethane-1,2-diamine	2138374: Inhibition of PRMT3 (unknown origin)	ic50	0.1190	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-(2-oxo-2-piperidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1340	uM
2-(isoquinolin-6-ylcarbamoylamino)-N,N-dimethylacetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1500	uM
N-cyclopropyl-2-(isoquinolin-6-ylcarbamoylamino)acetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1580	uM
methyl (2S)-1-[2-(isoquinolin-6-ylcarbamoylamino)acetyl]pyrrolidine-2-carboxylate	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1660	uM
1-(1-methylisoquinolin-6-yl)-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.1940	uM
1-[2-[1-(aminomethyl)cyclohexyl]ethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.2910	uM
N-cyclopentyl-2-(isoquinolin-6-ylcarbamoylamino)acetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.2920	uM
1-(2-cyclopentylethyl)-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.2950	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-[(4-nitrophenyl)methyl]urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.3000	uM
2-[2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-1-phenylguanidine	2127550: Inhibition of human PRMT3 using Histone H3 as substrate and SAM as cofactor by radiometric HotSpot assay	ic50	0.3210	uM
2-[2-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-1-(2-bromophenyl)guanidine	2127582: Inhibition of PRMT3 (unknown origin)	ic50	0.3210	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-[2-(4-fluorophenyl)-2-oxoethyl]urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.3600	uM
1-[2-(cyclohexen-1-yl)ethyl]-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.4210	uM
2-(isoquinolin-6-ylcarbamoylamino)-N-methoxy-N-methylacetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.4760	uM
N-cyclohexyl-2-(isoquinolin-6-ylcarbamoylamino)acetamide	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.4770	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-phenacylurea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.4800	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-(2-cyclohexyl-2-hydroxyethyl)urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.4900	uM
N’-[[2-[4,4-bis(methoxymethyl)cyclohexyl]oxyphenyl]methyl]-N,N’-dimethylethane-1,2-diamine;dihydrochloride	2069842: Inhibition of PRMT3 (unknown origin) by AlphaLISA assay	ic50	0.4930	uM
1-(2-cyclohexylethyl)-3-isoquinolin-6-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.5400	uM
N’-methyl-N’-[[4-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methyl]ethane-1,2-diamine	1801573: PRMT Biochemical Assays from Article 10.1021/acschembio.5b00839: “A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.”	ki	0.5500	uM
1-(1-oxo-3H-2-benzofuran-5-yl)-3-(2-oxo-2-piperidin-1-ylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.7570	uM
1-isoquinolin-6-yl-3-(2-phenylethyl)urea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.8330	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-(2-cyclohexyl-2-oxoethyl)urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.8400	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-[(4-methylsulfonylphenyl)methyl]urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	0.8500	uM
(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-cyanopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	1636911: Inhibition of PRMT3 (unknown origin)	ic50	0.8700	uM
(2S)-1-[[2-[[3-chloro-4-(1,3-thiazol-2-yl)phenyl]methoxy]phenyl]methyl-methylamino]-3-(methylamino)propan-2-ol	2104090: Inhibition of PRMT3 (unknown origin)	ic50	0.9420	uM
1-(2-oxo-2-piperidin-1-ylethyl)-3-quinazolin-7-ylurea	1472768: Inhibition of PRMT3 (unknown origin) using C-terminally biotinylated histone H4 as substrate in presence of [3H]S-adenosylmethionine by scintillation proximity assay	ic50	0.9670	uM
1-(1,2,3-benzothiadiazol-6-yl)-3-(2-cyclohexylethyl)urea	729422: Inhibition of PRMT3 (unknown origin) using histone H4 (1 to 24) as substrate after 1 hr by scintillation proximity assay in presence of [3H]-S-adenosylmethionine	ic50	1.0000	uM
(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	738921: Inhibition of PRMT3 (unknown origin) using [3H]SAM assessed as inhibition of biotinylated-H4 (1 to 24 amino acid residues) methylation after 1 hr by scintillation proximity assay	ki	1.1500	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	increases abundance, increases expression, decreases expression, affects cotreatment	2
Dexamethasone	decreases expression, affects cotreatment	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
SGC707	affects folding, affects binding, decreases activity	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	affects expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
1-nitropyrene	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	increases methylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

148 unique, capped per target: 145 binding, 3 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1037276	Binding	Inhibition of PRMT3	Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)–Hit to Lead studies. — Bioorg Med Chem Lett
CHEMBL5444955	Functional	Affinity Phenotypic Cellular interaction: (Western Blot (inhibitor of H4R3 methylation in MCF-7 cells)) EUB0000261b PRMT3	Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KW00	InCELL Hunter A549 PRMT3 Methyltransferase	Cancer cell line	Male
CVCL_TH12	HAP1 PRMT3 (-) 1	Cancer cell line	Male
CVCL_TH13	HAP1 PRMT3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.